FY2025 Earnings Forecast for IN8bio Issued By HC Wainwright

IN8bio, Inc. (NASDAQ:INAB) – Analysts at HC Wainwright lifted their FY2025 earnings estimates for shares of IN8bio in a research report issued on Wednesday, January 14th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.66) per share for the year, up from their prior forecast of ($5.71). The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for IN8bio’s Q4 2025 earnings at ($0.18) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.09) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($0.25) EPS, FY2029 earnings at $0.25 EPS and FY2030 earnings at $0.62 EPS.

Other analysts have also recently issued reports about the company. Mizuho set a $4.00 target price on IN8bio in a report on Monday, October 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research note on Wednesday, October 8th. Finally, Zacks Research raised shares of IN8bio from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $92.00.

IN8bio Stock Up 5.0%

NASDAQ INAB opened at $2.32 on Friday. IN8bio has a twelve month low of $1.17 and a twelve month high of $12.53. The company has a market capitalization of $9.79 million, a price-to-earnings ratio of -0.43 and a beta of -0.01. The stock has a fifty day simple moving average of $1.89 and a 200 day simple moving average of $2.08.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.35.

Hedge Funds Weigh In On IN8bio

Several institutional investors have recently added to or reduced their stakes in INAB. Citadel Advisors LLC purchased a new position in IN8bio in the third quarter valued at approximately $54,000. Two Sigma Investments LP purchased a new position in IN8bio in the 3rd quarter worth approximately $107,000. Finally, Stonepine Capital Management LLC bought a new stake in shares of IN8bio during the 2nd quarter worth $172,000. Institutional investors own 92.05% of the company’s stock.

Key IN8bio News

Here are the key news stories impacting IN8bio this week:

• Positive Sentiment: HC Wainwright substantially raised near‑term quarterly and FY estimates — cutting Q1–Q4 2025/2026 per‑share loss forecasts from roughly ($1.20) to the ($0.21)–($0.33) range and lifting FY2026 from ($5.71) to ($1.09), signaling materially smaller expected losses in the coming year. HC Wainwright research note
• Positive Sentiment: The firm also pushed out a path to profitability: HC Wainwright models positive EPS by FY2029 ($0.25) and stronger gains in FY2030 ($0.62), which provides a clearer long‑term upside scenario for INAB if clinical and commercial execution follow the plan. HC Wainwright research note
• Neutral Sentiment: Despite the upgrades, HC Wainwright’s forecasts still expect a FY2026 loss (~($1.09)) and the consensus full‑year estimate remains negative (~($0.56)), reflecting ongoing execution, clinical and funding risks typical for small biotech. The company’s market cap is very small, so analyst shifts can cause large share moves but also maintain high volatility.

IN8bio Company Profile

IN8bio, Inc (NASDAQ: INAB) is a clinical-stage biotechnology company focused on the development of novel immunotherapies for the treatment of cancer and neurodegenerative disorders. The company leverages insights into the body’s innate and adaptive immune systems to engineer cell-based products designed to target solid tumors, brain injuries and cognitive decline.

IN8bio’s pipeline is built on two proprietary platforms. The ENACT™ platform centers on allogeneic gamma delta T cell therapies aimed at solid tumors, with lead candidates advancing through early-stage clinical trials in glioblastoma and other oncology indications.